Bayer AG - Stockholders' Newsletter First Quarter 2007 - New registrations for Bayer HealthCare

News

New registrations for Bayer HealthCare

The oral contraceptive YAZ® is now also approved in the U.S. for the treatment of moderate acne in women.

Zoom image

The oral contraceptive YAZ® is now also approved in the U.S. for the treatment of moderate acne in women.

Berlin. Bayer HealthCare has received new marketing authorizations for a number of products. The innovative long-acting contraceptive system Mirena® from Bayer Schering Pharma AG, Germany* (BSP) was launched on the Japanese market in April 2007 under the trade name Mirena® 52 mg. The U.S. Food and Drug Administration (FDA) has approved a new indication for BSP’s oral contraceptive YAZ®, which can now be used in the United States to treat moderate acne in women. Fludara® Oral from BSP’s hematology portfolio has received marketing approval in Japan for therapy of a malignant disease of the lymphatic system. Also in Japan, BSP recently received approval for its novel cholesterol-lowering drug ZETIA®, which will be co-marketed by Bayer Yakuhin Ltd. and Schering-Plough K.K. Japan. This co-marketing agreement is part of Bayer’s strategic pharmaceuticals alliance with Schering-Plough, which was announced in 2004.

The names "Bayer Schering Pharma" or "Schering" as used in this publication always refer to Bayer Schering Pharma AG, Berlin, Germany, or its predecessor, Schering AG, Berlin, Germany, respectively.